The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Indoxyl sulfate (IS) is a uremic toxin that accelerates the progression of chronic kidney disease (CKD). AST-120 (Kremezin®; Kureha Corporation, Tokyo, Japan) removes indole, which is the precursor of IS, in the intestine, and reduces the accumulation of IS. This drug has been shown to retard the deterioration of renal function in CKD patients through reducing the levels of IS.

IS was reported to promote aortic calcification and stimulate the proliferation of vascular smooth muscle cells (VSMC). IS also inhibits endothelial proliferation and wound repair. With this background, the investigators will performed the study whether AST-120 improve the endothelial dysfunction in CKD patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of An Oral Absorbent AST-120 in Late-stage Chronic Kidney Disease (CKD) Patients.

NCT01681303

Chronic Kidney Disease AST-120

COMPLETED PHASE4

Indoxyl Sulfate Induces Leukocyte-endothelial Interactions Through Up-regulation of ICAM-1 in Acute Kidney Injury

NCT02061566

Renal Function Disorder

UNKNOWN

Exploring the Mechanisms of Indoxyl Sulfate Production by Oral Tryptophan Challenge Test

NCT04117191

Healthy Chronic Kidney Diseases

COMPLETED NA

Impact of Low Protein Diet Supplemented With Ketoanalogues Supplementation on Uremic Toxins Production

NCT03959228

Renal Failure

UNKNOWN PHASE3

Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease

NCT00456859

Kidney Failure, Chronic

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to examine whether Kremezin, Indoxyl sulfate lowering agent improve endothelial dysfunction in stage 3,4 chronic kidney disease patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Failure, Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AST-120

AST-120 administration 2g three times a day

Group Type EXPERIMENTAL

Kremezin

Intervention Type DRUG

AST-120 2g three times a day

Control

Control Chronic Kidney disease stage 3,4

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Kremezin

AST-120 2g three times a day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AST-120 (Kremezin) 2g three times a day

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with Chronic kidney disease (Stage3 - Stage4)
* Patients who are able and willing to understand, sign and date an informed consent document, and authorize access to protected health information